Resolve diagnostic unknowns fast
Infectious diseases can be caused by many distinct viral, bacterial and parasitic pathogens. But these pathogens often result in similar symptoms, making definitive diagnosis difficult.
Traditional diagnostic methods, such as bacterial culture and microscopy, take too long or are not sensitive enough. In contrast, syndromic testing uses multiplex PCR to provide the fast turnaround time and high sensitivity healthcare providers need to make an accurate diagnosis.
The benefits of syndromic testing go beyond fast results
Syndromic testing can help eliminate the guesswork of diagnosing infectious diseases and facilitate fast clinical decision making. As a result, syndromic testing has many positive downstream effects for healthcare institutions. Many clinical publications show that syndromic testing can improve patient care, support lab efficiency and reduce healthcare costs.
Syndromic testing article hub
Get the latest insights on syndromic testing for infectious diseases
How does syndromic testing work?
Syndromic testing provides qualitative detection and identification of multiple viral, bacterial and/or parasitic pathogens in a sample using highly multiplexed real-time PCR. While older molecular methods required multiple different singleplex tests to be run, syndromic testing can provide results for more than 20 pathogens with just one multiplex test. This saves time and resources and increases lab efficiency.How are pathogens detected in syndromic testing?
The real-time PCR reaction that mediates detection of pathogen targets in a patient sample involves four simple steps that take around one hour. In this simplified example, the specific pathogen target being detected is viral RNA.What do syndromic test results look like?
Unlike traditional laboratory techniques, which can sometimes produce subjective results, syndromic testing provides a binary answer for pathogen detection: positive or negative.
Bring the accuracy of syndromic testing to your lab
Get in touch to learn how.
Recommended reading
References
- Martinez, R.M, et al. Clinical Virology Symposium 2016. Poster #C-368
- Zhu et al., Clin Pediatr, 2019, 58(2):185-190
- Rappo U, et al. J Clin Micro 2016
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.